Research on Tesamorelin Peptide?
Reduction of Visceral (Abdominal) Fat: Research has shown that Tesamorelin effectively reduces visceral adipose tissue (VAT) by 15%–20% over 6–12 months in individuals with HIV-associated abdominal fat accumulation.
In clinical studies, patients achieving an ≥8% VAT reduction experienced significant metabolic benefits, including improved triglyceride levels, enhanced adiponectin levels, and better glucose homeostasis. These changes were sustained over 52 weeks, highlighting tesamorelin’s dual role in reducing harmful abdominal fat and improving endocrine and metabolic health in patients with central fat accumulation (1).
Improved Lipid Profile: Research indicates that Tesamorelin improves lipid profiles by reducing the quantity of visceral adipose tissue (VAT) and enhancing fat quality. Studies in HIV patients with central adiposity showed that tesamorelin decreased VAT volume by 15.2%, leading to reduced cardiovascular risk (2).
Additionally, it increased VAT and subcutaneous fat density (measured in Hounsfield Units), indicating smaller, healthier fat cells. This dual effect, reducing the amount of harmful fat while improving the quality of remaining fat, along with improved triglyceride levels (−50 mg/dL) and cholesterol ratios, highlights tesamorelin’s potential to support metabolic health in patients with central fat accumulation (3).
Better Glucose Metabolism:Tesamorelin demonstrates a neutral effect on glucose regulation while offering metabolic benefits (4). In a 12-week study with type 2 diabetes patients, tesamorelin did not significantly alter insulin sensitivity, fasting glucose, HbA1c, or overall diabetes control.
However, it reduced total cholesterol and non-HDL cholesterol levels, highlighting its positive impact on lipid metabolism (5). These findings suggest tesamorelin can improve metabolic health without compromising glycemic control, even in individuals with diabetes.
Body Composition Improvements: Research suggests that Tesamorelin improves body composition by reducing visceral adipose tissue (VAT) and enhancing muscle mass and quality. In HIV patients with abdominal obesity, tesamorelin reduced VAT by 15%–20% over 26–52 weeks while preserving subcutaneous fat (6).
It also increased skeletal muscle density and area, particularly in the rectus and psoas muscles, improving muscle quality. These changes, combined with improved body image and lipid profiles, highlight tesamorelin’s potential for enhancing metabolic and physical health (7).
Potential Benefit for Non-Alcoholic Fatty Liver Disease (NAFLD/NASH): Studies have demonstrated that Tesamorelin significantly reduces liver fat and improves markers of non-alcoholic fatty liver disease (NAFLD). In HIV patients with abdominal obesity, tesamorelin reduced hepatic fat fraction (HFF) by 37% over 12 months, with 35% achieving normal HFF levels (<5%) (8).
It also improved liver enzymes (ALT and AST) in patients with elevated baseline levels, particularly in those with significant VAT reduction. These findings highlight tesamorelin’s potential to address NAFLD in HIV patients (9).
Possible Cognitive Benefits: Tesamorelin studies have shown potential cognitive benefits by increasing IGF-1 levels, which are crucial for brain function. In HIV patients with abdominal obesity, tesamorelin reduced waist circumference and showed a trend toward improved neurocognitive performance over six months, though results were not statistically significant. IGF-1 and growth hormone pathways are linked to brain health, suggesting tesamorelin’s potential to mitigate neurocognitive impairment, though further studies are needed to confirm long-term cognitive effects.
Buy Tesamorelin Pre-Mixed Peptide from Peptide Works. The pre-mixed pen kit is available in 2mg cartridges, supplied with a cartridge pen, needle tips, and carry case for easy and accurate use.
References
(1) T L. Stanley, J Falutz, C Marsolais, et al (2012) Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin – Clinical Infectious Diseases, Volume 54, Issue 11, 1 June 2012, Pages 1642–1651.
(2) J E Lake, K La, K M Erlandson, et al (2021) Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity – AIDS, 2021 Jul 15, Volume 35 (Issue 9), Pages 1395–1402.
(3) J Falutz, S Allas, K Blot, et al (2007) Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV – New England Journal of Medicine, 2007, Volume 357, Pages 2359-2370.
(4) S-H Kim and M-J Park (2017) Effects of growth hormone on glucose metabolism and insulin resistance in human – Ann Pediatr Endocrinol Metab, 2017 Sep 28, Volume 22 (Issue 3), Pages 145–152.
(5) D R Clemmons, S Miller, and J-C Mamputu (2017) Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial – PLoS One, 2017 Jun 15, Volume 12 (Issue 6), Page e0179538.
(6) J Falutz, J-C Mamputu, D Potvin, et al (2010) Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data – The Journal of Clinical Endocrinology & Metabolism, Volume 95, Issue 9, 1 September 2010, Pages 4291–4304.
(7) S. Adrian, A. Scherzinger, A. Sanyal, et al (2019) The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV – The Journal of Frailty & Aging, Volume 8, Issue 3, July 2019, Pages 154-159.
(8) T L Stanley, L T Fourman, M N Feldpausch, et al (2019) Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial – The Lancet HIV, Volume 6, Issue 12, December 2019, Pages e821-e830.
(9) L T Fourman, N Czerwonka, M N Feldpausch, et al (2017) Visceral Fat Reduction with Tesamorelin Is Associated with Improved Liver Enzymes in HIV – AIDS. 2017 Oct 23, Volume 31 (Issue 16), Pages 2253–2259.
(10) M H Aguiar-Oliveira, M CS Boguszewski, D L Rovaris, et al (2025) Growth hormone and IGF-1 actions in the brain and neuropsychiatric diseases – Physiology (Bethesda), 2025 Jul 7, Volume 41 (Issue 1):0.
(11) R J Ellis, F Vaida, K Hu, et al (2025) Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity – J Infect Diseases, 2025 Jun 2, Volume 231 (Issue 5), Pages 1230-1238.